Psychometric validation and interpretation of the Nocturia Impact Diary in a clinical trial setting.

Psychometric evaluation of the Nocturia Impact (NI) Diary was conducted to support its use as a trial endpoint.

As part of a randomized, controlled Phase 2 clinical trial investigating a novel drug candidate for nocturnal polyuria, adult nocturia patients completed the NI Diary and a voiding diary for three nights preceding their clinic visit at Baseline and Weeks 1, 4, 8, and 12 (end of treatment). Exit interviews were conducted to obtain patient impressions of the NI Diary.

A total of N = 302 participants were included. Confirmatory factor analysis (CFA) indicated that the 11-item measure is unidimensional with values of CFI, TLI, and RMSEA meeting relevant thresholds. Good internal consistency (Cronbach's α 0.941) and test-retest reliability (intra-class correlation coefficients 0.730-0.880). Convergent validity with two reference measures was demonstrated with strong correlations of 0.573-0.730 were shown. Significant differences (P = 0.0018, standardized effect size = 0.372) between groups defined by number of night-time voids supported known-groups validity. Exit interviews in 66 patients indicated all participants experienced improvement in at least 1 NI Diary item and that a 1-point improvement on the item response scale and 1-void reduction per night (associated with an average best cut point on ROC analysis of - 11.6) constituted meaningful improvement. Anchor and distribution-based analyses identified a meaningful change threshold of - 15 to - 18 points on the NI Diary.

The NI Diary is a reliable and valid patient-reported psychometric instrument which is fit-for-purpose to evaluate the impact of nocturia on patient quality of life in the clinical trial setting. Trial registration number and registration date NCT03201419; June 28, 2017.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2021 Dec 21 [Epub ahead of print]

Stacie Hudgens, Amy Howerter, Ela Polek, Fredrik L Andersson

Clinical Outcomes Solutions, Tucson, AZ, USA. ., Clinical Outcomes Solutions, Tucson, AZ, USA., Clinical Outcomes Solutions, Folkestone, UK., Ferring Pharmaceuticals A/S, Copenhagen, Denmark.